Empagliflozin
Indication
Treating chronic heart failure with reduced ejection fraction (NICE TA773)
NICE TA773 - Empagliflozin for treating chronic heart failure with reduced ejection fraction
Brand:
Nice TA:
773
Commissioning responsibility:
CCG
PbR excluded:
No
Background
1.1 Empagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:
-
an angiotensin-converting enzyme (ACE) inhibitor or angiotensin 2 receptor blocker (ARB), with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA), or
-
sacubitril valsartan with a beta blocker and, if tolerated, an MRA.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist